FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W41005079> ?p ?o ?g. }

• W41005079 endingPage "1006" @default.
• W41005079 startingPage "994" @default.
• W41005079 abstract "This survival analysis was conducted at Ubon Ratchathani Cancer Center to determine the prognostic factors for survival of patients with stage IIIA, stage IIIB, and stage IV non-small-cell lung cancer (NSCLC) patients treated at the center between 1997-2001. The study sample included 210 patients with non-small-cell lung cancer. Diagnosis and staging were defined employing the TNM system. The majority of lung cancer patients were smokers (66.7%), lived in Ubon Ratchathani Province (40.0%), male (77.6%), and agriculturalists (74.8%). Seventy-seven percent of patients died within five years, 19.5% were lost to follow-up and 2.9% were still alive in 2003. The estimated median survival time was 6.3 months (95% CI 5.4-7.3); the median survival times for stages IIIA, IIIB, and IV were 16.3, 7.0, and 4.5 months, respectively. The overall 1-, 2- and 3-year survival rates of NSCLC were 28.9, 7.9, and 3.3, respectively. The differences in survival of patients in the various stages of the disease were statistically significant (p < 0.0001), adjusted for age and sex. Treatment with combination methods and at an early stage in the disease were associated with significant prolongation of survival. For stage IIIA, the estimated median survival times by treatment with chemotherapy was 7.0 months, radiotherapy was 16.0 months, surgery and others 16.3 months, and chemotherapy plus radiotherapy was 19.5 months. However, only chemotherapy versus surgery and others was significantly different (p = 0.0307). The median survival times for stage IIIB patients treated with chemotherapy, radiotherapy, surgery and others, chemotherapy and radiotherapy, and supportive treatment were 7.0, 7.0, 9.0, 14.7, and 3.0 months, respectively. The differences between surgery and others versus supportive treatment, chemotherapy and radiotherapy versus supportive treatment were significantly different (p = 0.0392, p = 0.0433, respectively). For stage IV, the median survival times for patients treated with chemotherapy, radiotherapy, chemotherapy and radiotherapy, and supportive treatment were 5.0, 4.3, 6.5, and 1.0 months, respectively. The differences between chemotherapy, radiotherapy, chemotherapy and radiotherapy versus supportive treatment, all were significantly different (p = 0.0020, p < 0.0001, p < 0.0001, respectively). The 2-year survival rates for stages IIIA, IIIB, and IV were 16.0, 4.1, and 2.2%, respectively. The results of the study show that stage IIIA has the longest survival time. They also show that appropriate treatment is a significant factor in improving the survival of lung cancer patients." @default.
• W41005079 created "2016-06-24" @default.
• W41005079 creator A5037218224 @default.
• W41005079 creator A5042623492 @default.
• W41005079 creator A5046712973 @default.
• W41005079 creator A5052529651 @default.
• W41005079 creator A5076342331 @default.
• W41005079 date "2005-07-01" @default.
• W41005079 modified "2023-09-30" @default.
• W41005079 title "Survival of patients with advanced non-small-cell lung cancer at Ubon Ratchathani Cancer Center, Thailand." @default.
• W41005079 cites W1481275904 @default.
• W41005079 cites W1748441280 @default.
• W41005079 cites W1817196311 @default.
• W41005079 cites W184971756 @default.
• W41005079 cites W1855747096 @default.
• W41005079 cites W1882728012 @default.
• W41005079 cites W1922104747 @default.
• W41005079 cites W1935885922 @default.
• W41005079 cites W1971881834 @default.
• W41005079 cites W1982492706 @default.
• W41005079 cites W2015795211 @default.
• W41005079 cites W2018277153 @default.
• W41005079 cites W2036268950 @default.
• W41005079 cites W2054385160 @default.
• W41005079 cites W2069831611 @default.
• W41005079 cites W2081604183 @default.
• W41005079 cites W2096698471 @default.
• W41005079 cites W2115290538 @default.
• W41005079 cites W2116483062 @default.
• W41005079 cites W2130652363 @default.
• W41005079 cites W2131928292 @default.
• W41005079 cites W2149636140 @default.
• W41005079 cites W2155053061 @default.
• W41005079 cites W2157000428 @default.
• W41005079 cites W2167729390 @default.
• W41005079 cites W2312703485 @default.
• W41005079 cites W2314635417 @default.
• W41005079 cites W2471903889 @default.
• W41005079 cites W2607353211 @default.
• W41005079 cites W28614743 @default.
• W41005079 cites W3145077989 @default.
• W41005079 cites W2098076970 @default.
• W41005079 cites W2275947889 @default.
• W41005079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16295558" @default.
• W41005079 hasPublicationYear "2005" @default.
• W41005079 type Work @default.
• W41005079 sameAs 41005079 @default.
• W41005079 citedByCount "5" @default.
• W41005079 countsByYear W410050792013 @default.
• W41005079 countsByYear W410050792021 @default.
• W41005079 countsByYear W410050792022 @default.
• W41005079 countsByYear W410050792023 @default.
• W41005079 crossrefType "journal-article" @default.
• W41005079 hasAuthorship W41005079A5037218224 @default.
• W41005079 hasAuthorship W41005079A5042623492 @default.
• W41005079 hasAuthorship W41005079A5046712973 @default.
• W41005079 hasAuthorship W41005079A5052529651 @default.
• W41005079 hasAuthorship W41005079A5076342331 @default.
• W41005079 hasConcept C10515644 @default.
• W41005079 hasConcept C121608353 @default.
• W41005079 hasConcept C126322002 @default.
• W41005079 hasConcept C141071460 @default.
• W41005079 hasConcept C146357865 @default.
• W41005079 hasConcept C151730666 @default.
• W41005079 hasConcept C2776256026 @default.
• W41005079 hasConcept C2776283816 @default.
• W41005079 hasConcept C2776694085 @default.
• W41005079 hasConcept C509974204 @default.
• W41005079 hasConcept C71924100 @default.
• W41005079 hasConcept C86803240 @default.
• W41005079 hasConceptScore W41005079C10515644 @default.
• W41005079 hasConceptScore W41005079C121608353 @default.
• W41005079 hasConceptScore W41005079C126322002 @default.
• W41005079 hasConceptScore W41005079C141071460 @default.
• W41005079 hasConceptScore W41005079C146357865 @default.
• W41005079 hasConceptScore W41005079C151730666 @default.
• W41005079 hasConceptScore W41005079C2776256026 @default.
• W41005079 hasConceptScore W41005079C2776283816 @default.
• W41005079 hasConceptScore W41005079C2776694085 @default.
• W41005079 hasConceptScore W41005079C509974204 @default.
• W41005079 hasConceptScore W41005079C71924100 @default.
• W41005079 hasConceptScore W41005079C86803240 @default.
• W41005079 hasIssue "4" @default.
• W41005079 hasLocation W410050791 @default.
• W41005079 hasOpenAccess W41005079 @default.
• W41005079 hasPrimaryLocation W410050791 @default.
• W41005079 hasRelatedWork W2138621581 @default.
• W41005079 hasRelatedWork W2277416945 @default.
• W41005079 hasRelatedWork W2349377541 @default.
• W41005079 hasRelatedWork W2350769263 @default.
• W41005079 hasRelatedWork W2359099389 @default.
• W41005079 hasRelatedWork W2360529269 @default.
• W41005079 hasRelatedWork W2362144381 @default.
• W41005079 hasRelatedWork W2368951709 @default.
• W41005079 hasRelatedWork W2370246965 @default.
• W41005079 hasRelatedWork W2389930763 @default.
• W41005079 hasVolume "36" @default.
• W41005079 isParatext "false" @default.

• next